Natto oligopeptide and its preparation method and application in thrombolysis and blood pressure reduction
Through the analysis of bioactive peptide database and complex protease cleavage technology, the prepared natto oligomeric peptide combined with natto kinase components has solved the problem of insufficient development and utilization of antithrombotic active ingredients in natto, significantly improving thrombolysis and degradation The pressure effect improves the treatment of thrombotic cardiovascular disease.
Patent Information
- Application Number
- CN202410603422.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-05-15
AI Technical Summary
The prior art is difficult to effectively develop and utilize antithrombotic active ingredients in natto, except for natto kinase, which leads to its limited application in the treatment of thrombotic cardiovascular and cerebrovascular diseases, and the enzymatic process is prone to destroy the activity of natto kinase.
Through the analysis of the bioactive peptide database, the molecular weight, N-terminal amino acid residue species, C-terminal amino acid residue species and net charge characteristics were determined. The molecular weight, N-terminal amino acid residue species and net charge characteristics were purified by complex protease cleavage and ion exchange chromatography to prepare a net charge of ±2 of less than 2000 Da. Bean oligopeptide, and mix it with the nattokinase component, and freeze-dried to obtain natto oligopeptide powder.
It improves the effect of natto products in thrombolysis and blood pressure reduction, enhances resistance to thrombus, reduces the risk of vascular endothelial injury and thrombosis, and significantly improves the symptoms of thrombotic cardiovascular disease.
Smart Images

Figure CN118325994B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of active peptide preparation, and specifically relates to a preparation method of natto oligopeptide and application thereof in thrombolysis and blood pressure reduction. Background Art
[0002] Thrombotic diseases, as typical cardiovascular diseases, seriously threaten human life and health, with high morbidity, high disability rate, high mortality rate and other characteristics. Its morbidity and mortality rate are at the forefront of various diseases, which not only brings great pain to patients, but also brings many impacts to the corresponding families. At the same time, a series of cardiovascular diseases including thrombosis are likely to be caused by sustained hypertension. At present, there are many thrombolytic agents used for thrombolytic therapy in clinical practice, such as streptokinase, urokinase, staphylokinase, single-chain urokinase, tissue-type plasminogen activator, etc. These thrombolytic agents have high thrombolytic specificity, but are also prone to allergic reactions and massive bleeding.
[0003] A large number of studies have shown that natto has medical and health benefits such as preventing osteoporosis, promoting blood coagulation, lowering blood pressure, and improving blood sugar. The reason why natto has good health benefits is closely related to the changes in the basic components of soybeans during its production process. The protein, fat, starch, isoflavones, etc. in soybeans will undergo complex biochemical reactions under the action of Bacillus natto, while retaining the original active ingredients, new active substances will be produced, such as nattokinase (NK), antioxidant peptides and antimicrobial peptides. Related studies have shown that nattokinase has certain effects on anti-platelet aggregation, in vitro thrombus dissolution, lowering blood pressure, and lowering blood lipids. Its thrombolytic mechanism includes nattokinase dissolving blood clots by directly hydrolyzing fibrin and plasmin substrates. It converts endogenous kinases into urokinase, degrades plasminogen activator inhibitors, and increases the level of tissue plasminogen activator, thereby dissolving thrombi.
[0004] However, research on natto components other than nattokinase, especially active peptide components, is still lacking. Yahui Song discovered peptides (RBPs) with high ACE inhibitory effects through fermentation of natto. The properties of the peptides were determined and it was found that RBPs can significantly reduce the incidence of spontaneously hypertensive rats and have a protective effect on the kidneys, thoracic aorta and heart. Kousuke Sato studied and determined the in vitro DPPIV inhibitory activity of natto isolated peptides. These studies have shown that natto contains a variety of active peptide components with physiological activity. Chinese invention patent application CN202310653994.6 A method for preparing natto and natto active peptides and products are obtained by inoculating composite bacteria to ferment soybeans, grinding mature fresh natto into a semi-fluid, drying and then crushing it to obtain natto active peptides. The above studies are all about separating the active peptide components inherent in the natto finished product, without further exploring and utilizing the natto protein / active peptide resources. Chinese invention patent application CN202311164212.9, a method for preparing a natto lipid-lowering peptide and its application, and Chinese invention patent CN202311164254.2, a method for preparing a natto antioxidant active peptide and its beverage, disclose a method for preparing a specific active natto peptide by enzymatic hydrolysis, but do not involve the most eye-catching anti-thrombotic effect of natto. At the same time, the acid-base environment of the enzymatic hydrolysis process and the high temperature environment during enzyme inactivation are extremely easy to destroy the activity of nattokinase. Lee KA et al. separated two anti-thrombotic active peptides SSGE and DEE from soy protein, which have the effect of inhibiting platelet aggregation. Although the soy protein components have undergone a certain degree of change after fermentation with natto bacteria, there is reason to believe that there is potential for the exploration of anti-thrombotic peptides in natto. Currently, the most common natto product on the market besides natto is natto freeze-dried powder, which is divided into different specifications according to the activity of nattokinase. Relevant research is mostly focused on how to increase the content of nattokinase by improving the fermentation process. The development and utilization of ingredients other than nattokinase is extremely rare. How to develop active ingredients other than nattokinase to enhance the improvement effect of natto products on thrombotic cardiovascular and cerebrovascular diseases is extremely important for maximizing the utilization of natto resources. Summary of the invention
[0005] In order to solve the problem of obtaining functional oligopeptides and further solve the problem of obtaining natto-derived polypeptides with anti-thrombotic effects, in the first aspect, according to the preparation method of oligopeptides in some embodiments of the present application, the method comprises:
[0006] Retrieve and determine the properties of peptides related to the functionality of biological objects in the bioactive peptide database, including molecular weight distribution, N-terminal amino acid residue type, C-terminal amino acid residue type and net charge;
[0007] The biological object is prepared into a peptide solution, and the types and quantities of the amino acids preceding the specific N-terminal amino acid of each peptide in the peptide solution are counted respectively;
[0008] The peptide bonds of all or part of the specific N-terminal amino acid and the preceding amino acid and / or the carboxyl-terminal peptide bond of the C-terminal amino acid are used as enzyme cleavage sites, and the enzyme cleavage sites are cleaved using a composite protease;
[0009] filtering the fragmented peptide solution to collect the peptide solution having a molecular weight that conforms to the molecular weight distribution in the characteristic;
[0010] The solution of the peptides meeting the molecular weight distribution in the characteristics is separated and purified, and the solution of the peptides meeting the net charge in the characteristics is collected to obtain the oligopeptide.
[0011] In a second aspect, according to the method for preparing the oligopeptide in some embodiments of the present application, comprising:
[0012] The bioactive peptide database was used to search and determine the characteristics of peptides related to the antithrombotic function of natto. The determined characteristics included a molecular weight of less than 2000 Da, an N-terminal amino acid residue of glycine G, a C-terminal amino acid residue of lysine K or arginine R, and a net charge of ±2;
[0013] preparing a solution of natto peptides, and counting the types and quantities of amino acid residues located before glycine G and the types and quantities of amino acid residues located before arginine R of each peptide in the peptide solution;
[0014] According to the statistical quantity, the tyrosine-glycine peptide bond, the phenylalanine-glycine peptide bond, the tyrosine-arginine peptide bond, the lysine carboxyl terminal peptide bond and the arginine carboxyl terminal peptide bond are used as enzyme cleavage sites according to the ranking, and the enzyme cleavage sites are divided by a composite protease, wherein the composite protease is composed of trypsin and chymotrypsin, wherein trypsin: chymotrypsin = 1: (1-3), the enzymatic hydrolysis temperature is 37-45°C, the enzymatic hydrolysis pH is 7.5-8.5, and the enzymatic hydrolysis time is 3-6h;
[0015] The solution of the cleaved peptides is filtered to collect the solution of peptides with a molecular weight lower than 2000 Da;
[0016] The solution of peptides with molecular weight lower than 2000 Da is separated and purified, and the solution of peptides with net charge ±2 is collected to obtain the first oligopeptide.
[0017] According to the preparation method of the oligopeptide in some embodiments of the present application, the method further includes mixing the solution of the peptide with a net charge of ±2 with the solution of the nattokinase component to obtain a second oligopeptide, wherein:
[0018] The solution of the nattokinase component is prepared, comprising:
[0019] Pass the natto powder solution through an ultrafiltration membrane with a molecular weight of 29000Da to obtain a first permeate;
[0020] Passing the first permeate through an ultrafiltration membrane with a molecular weight of 26000Da to obtain a second permeate and a second intercepted liquid;
[0021] Wherein, the second intercepted liquid is a solution of the nattokinase component;
[0022] According to the method for preparing oligopeptides in some embodiments of the present application, the natto is prepared from soybeans.
[0023] According to the preparation method of the oligopeptide in some embodiments of the present application, the method further includes freeze-drying the first oligopeptide to obtain natto oligopeptide powder.
[0024] According to the preparation method of the oligopeptide in some embodiments of the present application, the method further includes freeze-drying the second oligopeptide to obtain natto oligopeptide powder.
[0025] According to the preparation method of oligopeptides in some embodiments of the present application, preparing the small peptide solution of natto includes adding digestive enzymes to the first permeate and the second intercepted liquid to obtain the small peptide solution of natto.
[0026] According to the method for preparing oligopeptides in some embodiments of the present application, the digestive enzyme is trypsin.
[0027] According to the preparation method of the oligopeptide in some embodiments of the present application, the step of filtering the solution of the cleaved peptide comprises filtering the solution of the cleaved peptide through a nanofiltration membrane with a molecular weight of 2000Da, wherein the permeate of the nanofiltration membrane is a solution of peptides with a molecular weight lower than 2000Da;
[0028] The step of separating and purifying the solution of peptides with a molecular weight lower than 2000Da comprises separating and purifying the solution of peptides with a molecular weight lower than 2000Da by ion exchange chromatography.
[0029] According to the method for preparing oligopeptides in some embodiments of the present application, the ion exchange chromatography comprises a strong cation exchange column.
[0030] According to the preparation method of the oligopeptide in some embodiments of the present application, the ion exchange chromatography includes a SP Sepharose High Performance strong cation exchange column. After loading, the strong cation exchange column is equilibrated with 20 mmol / L PB (pH 6.0), and elution is performed with a 0-40 min: 0-1 M NaCl concentration gradient. The eluate is collected for 11-19 min to obtain a solution of the peptide with a net charge of ±2.
[0031] According to the preparation method of the oligopeptide in some embodiments of the present application, the peptides in the natto peptide solution are sequenced, and according to the sequencing, the types of amino acid residues located in front of glycine G and the types and quantities of amino acid residues located in front of arginine R of each peptide in the peptide solution are counted respectively;
[0032] Among them, the steps of sorting according to statistical quantity include:
[0033] The amino acid residues in front of the different types of glycine G are sorted by quantity;
[0034] The amino acid residues in the R position before different types of arginine are ranked according to their quantity;
[0035] According to the ranking of the number of amino acid residues before glycine G of different types, the types of amino acid residues with the largest number or the first few are cut with the peptide bond of glycine G to obtain a peptide with the N-terminal amino acid residue type of glycine G;
[0036] According to the ranking of the number of amino acids in front of different types of arginine R, the type of amino acid residue with the largest number or the first few largest numbers is cut with the peptide bond of arginine R to obtain a peptide whose N-terminal amino acid residue type is arginine R;
[0037] The peptide bond at the carboxyl terminal of lysine is cleaved to obtain a peptide whose C-terminal amino acid residue is lysine K;
[0038] The arginine carboxyl terminal peptide bond of a peptide whose non-N-terminal amino acid residue is arginine R is cleaved to obtain the C-terminal amino acid residue type arginine R, and the arginine R of a peptide whose N-terminal amino acid residue type is arginine R is cleaved to obtain free L-arginine.
[0039] In a third aspect, an oligopeptide prepared according to the method described in any one of some embodiments of the present application.
[0040] In a fourth aspect, the oligopeptide in some embodiments of the present application is used in the preparation of a thrombolytic drug or in the preparation of a drug for treating hypertension or in the preparation of a drug for simultaneous thrombolysis and hypotension.
[0041] Beneficial effects:
[0042] (1) In the first aspect of the present invention, the physicochemical properties of functional peptide segments are analyzed through an online database, and the molecular weight distribution, the type of N-terminal amino acid residue, the type of C-terminal amino acid residue and the net charge are selected as characteristics to determine the cleavage site. The small peptide is cut by a composite protease at the cleavage site, and further filtered and separated and purified to meet the molecular weight and net charge requirements of the characteristics, so as to obtain a small peptide with corresponding characteristics, so that it can express the target functionality.
[0043] (2) In a specific example of the present invention, the physicochemical properties of antithrombotic peptides are analyzed through an online database, and peptides with antithrombotic activity are released from natto as much as possible. The nattokinase component is combined to further improve the thrombolytic activity of the natto freeze-dried powder raw material. At the same time, in this process, the amount of free L-arginine (L-Arginine, referred to as L-Arg) in the raw material is increased, and the vasodilation and blood pressure regulation are further achieved, and the risk of thrombosis caused by endothelial damage caused by high-pressure erosion of blood vessels and activation of endogenous and exogenous coagulation systems is reduced, and the symptoms of thrombotic cardiovascular diseases such as atherosclerosis are alleviated.
[0044] (3) L-Arg is the only substrate for the production of nitric oxide (NO) in all mammals, and NO can promote vasodilation, help increase blood flow and improve blood circulation, help regulate blood pressure, and inhibit platelet aggregation and coagulation, thereby reducing the risk of thrombosis. Experimental results obtained on animals and clinical studies have shown that L-Arg has a certain effect on platelets, coagulation process and fibrinolytic system through the NO pathway. The present invention uses composite enzyme cleavage to increase the amount of characteristic small peptides and achieve the target function. On the other hand, the role of L-Arg is considered in the cleavage, and the composite enzyme is designed to achieve cleavage with characteristic small peptides as the target, while also increasing the amount of free L-Arg, so that the present invention can have both thrombolytic and antihypertensive effects, and the antihypertensive effect can also reduce the risk of thrombosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 Distribution of amino acid residue types before glycine.
[0046] Figure 2 Distribution of amino acid residue types before arginine.
[0047] Figure 3 Distribution of N-terminal amino acid residues.
[0048] Figure 4 Distribution of C-terminal amino acid residues. DETAILED DESCRIPTION
[0049] The present invention is further described below by way of examples. It should be noted that the examples do not limit the scope of protection claimed for the present invention.
[0050] The present invention provides a preparation method of natto oligopeptide and application thereof in thrombolysis and blood pressure reduction. The preparation method comprises the following steps:
[0051] S1: The natto freeze-dried powder prepared by fermentation of Bacillus natto is used as raw material, dissolved in physiological saline, separated by ultrafiltration membrane, and the solution of components with a molecular weight between 26000-29000Da is intercepted as nattokinase component F1. The remaining components after ultrafiltration membrane separation of nattokinase component F1 are called natto component F2 solution, i.e., the solution of components with a molecular weight less than 26000Da and a molecular weight greater than 29000Da.
[0052] S2: Search the keyword "antithrombotic" in the "Bioactive peptides" module from the BIOPEP database to analyze the characteristics of active peptides with antithrombotic properties, including basic properties such as molecular weight distribution, N-terminal amino acid residue type, C-terminal amino acid residue type, and net charge. In the present invention, the characteristic information specifically refers to the characteristics of potential antithrombotic active peptides with a molecular weight of less than 2000Da, an N-terminal amino acid residue type of glycine G, a C-terminal amino acid residue type of lysine K or arginine R, and a net charge of ±2.
[0053] S3: After the natto component F2 remaining after the nattokinase component F1 is cut off, it is digested by a digestive enzyme such as trypsin for 4 hours to obtain a first natto hydrolysate, and the first natto hydrolysate is subjected to peptide segment analysis by LC-MS / MS and de novo sequencing. Based on the above characteristics, the present invention aims to achieve that in the obtained oligopeptide, part or all of the N-terminal amino acid residues are glycine, and the C-terminal amino acid residues are lysine K or arginine R. The C-terminal amino acid residues are lysine K and arginine R, and the lysine carboxyl terminal peptide bond and the arginine carboxyl terminal peptide bond are the target enzyme cleavage sites, and the cleavage can be performed. For example, if trypsin is used for enzyme cleavage, an oligopeptide with a C-terminal amino acid residue of lysine K or arginine R can be obtained.
[0054] In order to obtain oligopeptides whose N-terminal amino acid residue is glycine, the types and quantities of amino acid residues located in front of glycine should be counted. However, considering the influence of enzymatic cleavage by composite proteases, if one composite protease can achieve enzymatic cleavage at multiple sites, it is difficult to achieve enzymatic cleavage of all types of amino acids in front of glycine and the peptide bond of glycine. In the present invention, the one with the largest number or the two with the largest number can be selected for enzymatic cleavage. On the one hand, an effective number of oligopeptides whose N-terminal amino acid residue is glycine can be obtained, and on the other hand, the difficulty of designing composite proteases for enzymatic cleavage can be reduced.
[0055] The present invention also counts the types and quantities of amino acid residues located in the front position of arginine, and designs a composite protease for the amino acid in the front position of arginine and the peptide bond of arginine to be carried out simultaneously with the above-mentioned enzyme cutting to obtain an effective number of oligopeptides with the type of N-terminal amino acid residue being arginine. According to the characteristics of step S2, the present invention does not need an oligopeptide with the type of N-terminal amino acid residue being arginine. However, the above-mentioned enzyme cutting of the present invention also obtains an oligopeptide with the type of C-terminal amino acid residue being arginine R. Therefore, for this part of oligopeptides, if an oligopeptide with the type of N-terminal amino acid residue being arginine is obtained, then the enzyme cutting performed because the oligopeptide with the type of C-terminal amino acid residue being arginine R is obtained makes the oligopeptide with the type of N-terminal amino acid residue being arginine form free L-arginine, and the present invention increases the free L-arginine in the product to play the role of vasodilation and lowering blood pressure. Therefore, the present invention also performs the above-mentioned types and quantities of amino acid residues located in the front position of arginine and enzyme cutting.
[0056] According to the above statistics, the enzyme cleavage sites are determined to design a composite protease combination, and the natto component F2 is enzymatically hydrolyzed according to the appropriate enzymatic hydrolysis conditions of the protease combination to obtain the second enzymatic hydrolyzate. The protein composite enzyme of the present invention should respond to both the enzymatic cleavage purpose of the above characteristics and the purpose of obtaining free L-arginine. The present invention uses a combination of trypsin and chymotrypsin to achieve the above purpose.
[0057] S4: The second enzymatic hydrolysate is separated by a nanofiltration membrane with a retention rate of 2000Da. The second enzymatic hydrolysate passes through the nanofiltration membrane, and the permeate is collected to obtain a solution of natto enzymatic hydrolysate component F3.
[0058] S5: further separating and purifying the solution of the natto hydrolysate component F3 by ion exchange chromatography, and collecting the solution of the natto hydrolysate component F4 with a net charge of ±2. The solution of the natto hydrolysate component F4 obtained here has the effects of thrombolysis and hypotension.
[0059] S6: The solution of the natto enzymatic hydrolysate component F4 is fully mixed with the solution of the nattokinase component F1 in step S1 which has certain anti-platelet aggregation, in vitro thrombus dissolving, blood pressure lowering, blood lipid lowering and other effects, and then freeze-dried to obtain natto oligopeptide powder.
[0060] From the above, in the first aspect, the present invention first separates the nattokinase component F1 to avoid the destruction of nattokinase in the subsequent enzymolysis process, and after preparing the natto hydrolysate component F4 with thrombolytic and antihypertensive effects, the nattokinase component F1 is mixed with the natto hydrolysate component F4 to further improve the therapeutic effect of the product and the amount of the product that can be used for treatment.
[0061] Based on the above, in the second aspect, the present invention analyzes and counts the peptide sequence of the natto component F2, takes the glycine pre-amino acid, the arginine pre-amino acid, the carboxyl end of lysine and the carboxyl end of arginine as the target enzyme cleavage sites, designs a composite protease preparation for enzyme cleavage, and obtains the natto hydrolysate component F3, so that the natto hydrolysate component F3 solution contains a high content of free L-arginine with a hypotensive effect, and at the same time increases the content of peptides with anti-thrombotic active peptides N-terminal and C-terminal amino acid residue type characteristics.
[0062] From the above, in the third aspect, the present invention further purifies the natto enzymatic hydrolysate component F4 with a molecular weight of less than 2000Da and a net charge of ±2 with potential antithrombotic activity through ultrafiltration membrane separation and ion exchange chromatography. Since arginine carries one positive charge, it can be eluted together with component F4 in the ion exchange chromatography. Therefore, the L-arginine obtained by enzymatic hydrolysis of the present invention does not cause improvement requirements in the separation and purification steps.
[0063] Embodiment 1: A method for preparing an oligopeptide comprises the following steps:
[0064] S1: 100g of natto freeze-dried powder prepared by fermenting soybean with Bacillus natto was dissolved in 1000ml of physiological saline, and the natto freeze-dried powder solution was passed through a 29000 molecular weight ultrafiltration membrane, and the permeate was taken to obtain a component with a molecular weight lower than 29000. The permeate was passed through a 26000 molecular weight ultrafiltration membrane, and the retentate was taken to obtain a component with a molecular weight higher than 26000 but lower than 29000, as the nattokinase component F1, and the first ultrafiltration retentate and the second ultrafiltration permeate were combined to form the natto component F2.
[0065] S2: The solution of natto component F2 was hydrolyzed by digestive enzymes such as trypsin for 4 hours to obtain natto hydrolyzate (enzymatic pH 8.5, enzymatic temperature 50°C). The purpose of enzymatic hydrolysis is to decompose proteins into small peptides (small molecule peptides, usually composed of 2 to 20 amino acid residues) by digestive enzymes. The enzymatic hydrolyzate was subjected to LC-MS / MS and De Novo sequencing for peptide segment analysis. The analysis conditions are as follows:
[0066] Column: C18, 3μm, 75μm*15cm, mobile phase: A: 0.1% Formic acid in water; B: 0.1% Formic acid in 80% Acetonitrile / H2O, chromatographic gradient:, spray voltage: 2.0kV, capillary temperature: 320℃, RF Lens:40, resolution setting: primary 120,000@m / z 200, secondary 30,000@m / z 200, parent ion scanning range: m / z 350-1550; daughter ion scanning range: start from m / z110, fragmentation mode: HCD.
[0067] The raw data collected by mass spectrometry were analyzed by de novo sequencing using the De Novo data analysis software PEAKS. The software parameters were set as follows:
[0068] Enzyme: No-specific, Variable modification: Oxidation (M), Deamidated (N, Q), Peptide mass tolerance: ±10ppm, Fragment mass tolerance: 0.02Da. (Enzyme: No-specific, Variable modification: Oxidation (M), Deamidated (N, Q), Peptide mass tolerance: ±10ppm, Fragment mass tolerance: 0.02Da.)
[0069] The types and numbers of amino acid residues before glycine and arginine were counted respectively. The results showed that the types and numbers of amino acid residues before glycine and arginine were distributed as follows: Figure 1 and Figure 2 As shown. It can be seen that the natto component F2 is enzymatically hydrolyzed with the peptide bond of tyrosine-glycine, the peptide bond of phenylalanine-glycine, the peptide bond of tyrosine-arginine, the peptide bond of the carboxyl end of lysine, and the peptide bond of the carboxyl end of arginine as the target enzyme cleavage sites, and the enzymatic hydrolysis conditions are as follows: trypsin: chymotrypsin = 1:1-3, enzyme addition amount: 1-3%, enzymatic hydrolysis temperature: 37-45°C, enzymatic hydrolysis pH: 7.5-8.5, enzymatic hydrolysis time 3-6 hours, and the second enzymatic hydrolyzate is obtained.
[0070] S3: Separate the second enzymatic hydrolysate through a nanofiltration membrane with a cutoff of 2000Da, collect the permeate to obtain natto enzymatic hydrolysate component F3, that is, obtain oligopeptides with a molecular weight lower than 2000Da.
[0071] S4: SP Sepharose High Performance strong cation exchange column was used to balance the cation exchange column with 20mmol / L PB (pH6.0). After loading and rebalancing, the present invention was eluted with a concentration gradient of 0-40min: 0-1M NaCl, and the eluate with a retention time of 11-19min was collected as the natto hydrolyzate component F4.
[0072] S5: The natto enzymatic hydrolysate component F4 and the nattokinase component F1 are fully mixed and freeze-dried to obtain natto oligopeptide powder.
[0073] Experimental Example 1. Determination of L-arginine content
[0074] The natto freeze-dried powder raw material used in step S1 of Example 1 and the natto oligopeptide powder obtained in step S5 were prepared into aqueous solution samples at a concentration of 100 μg / ml, and standard L-arginine was configured into standard solutions with concentrations of 0.625, 1.25, 2.5, and 5.0 μmol / ml with deionized water. 10 μL of each sample and standard product was added to 20 μL of 6-aminoquinoline-N-hydroxysuccinimide carbamate solution for derivatization, and high performance liquid chromatography-fluorescence detection was performed on the free L-arginine content in the two samples and the standard product. The free L-arginine content in the natto freeze-dried powder sample was 0.23 g / 100 g, and the free L-arginine content in the natto oligopeptide powder sample was 5.5 g / 100 g, indicating that the enzymatic cleavage effect of the peptide bond before and after the arginine in the natto freeze-dried powder protein was good, and the free L-arginine obtained by enzymatic cleavage was eluted together with the antithrombotic active peptide component in the strong cation exchange column. Compared with the natto freeze-dried powder raw material, the content of free L-arginine in natto oligopeptide powder is greatly increased.
[0075] Experimental Example 2. Peptide Analysis
[0076] The peptide sequence in the natto oligopeptide powder was determined by the same detection method as step S2 in Example 1, and the proportion of the N-terminal and C-terminal amino acid residues was counted. The results are as follows: Figure 3 , Figure 4 As shown in the figure, the main types of N-terminal amino acid residues in natto oligopeptide powder are glycine, and the main types of C-terminal amino acid residues are lysine and some arginine, tyrosine and tryptophan, which meet the target enzymatic hydrolysis effect.
[0077] Experimental Example 3. Chronic thrombosis model in spontaneously hypertensive rats
[0078] Natto freeze-dried powder and natto oligopeptide powder were prepared into 1g / ml paste with deionized water. 8 WKY rats were used as the control group; 24 SHR were randomly divided into 3 groups, 8 rats in each group, namely: model group, natto freeze-dried powder group (10g / kg·d), and natto oligopeptide powder high-dose group (10g / kg·d). SHR rats were anesthetized by intraperitoneal injection of 3% sodium pentobarbital (2mL / kg) and then the neck skin was longitudinally incised about 2cm from the midline, and the bilateral carotid arteries were carefully separated. A homemade plastic pad was placed under the carotid aorta to protect the tissue around the blood vessels; a small piece of filter paper ring with 2μL 50% FeCl3 solution was applied to this section of artery, and the filter paper ring was gently clamped with tweezers to make it close to the arterial wall for 50 minutes before being removed, forming a non-occlusive arterial thrombus, which occupied about 1 / 3 to 1 / 2 of the vascular cavity. The local tissue was rinsed with normal saline. The wound was sprinkled with an appropriate amount of penicillin to prevent infection, and then sutured layer by layer and returned to the cage for feeding. In the sham operation group, a small piece of filter paper with 2 μL of saline was applied to this section of artery, which was removed after 50 minutes and the wound was sutured. Starting from the second day after modeling, the drug group was gavaged according to the above dose, and the control group and the model group were given an equal amount of saline for one week. The blood pressure of rats in each group was measured by sphygmomanometer on the 1st, 3rd, 5th and 7th days after administration. Each rat was measured 5 times in total, and the SBP value was read and recorded each time, and the average value was taken; on the 8th day, 20% urethane was used for anesthesia, and the blood vessels at the thrombus site of the carotid aorta were taken, placed on filter paper to absorb the residual blood, and weighed with an electronic analytical balance.
[0079] The results are shown in Table 1. The SBP value of spontaneously hypertensive rats in SHR was much higher than that in the control group, and due to the formation of non-occlusive thrombus in the carotid artery, the blood pressure was higher than that of normal SHR. There was no significant difference between the SHR after intragastric administration of natto freeze-dried powder and the model group, while the blood pressure of SHR after intragastric administration of natto oligopeptide powder gradually decreased within 1 week after administration, showing a significant difference from the model group, indicating that natto oligopeptide powder has a good effect of relaxing blood vessels and lowering blood pressure. At the same time, the results of the carotid artery thrombosis mass of SHR rats in each group showed that the thrombus mass of the natto freeze-dried powder group and the natto oligopeptide powder group was significantly lower than that of the model group (p<0.01). Among them, the natto oligopeptide powder intervention group reduced further thrombosis caused by endothelial cell damage due to the anti-platelet aggregation and anti-coagulation effects of the anti-thrombotic peptide component F4, on the basis of the fibrinolytic effect of the nattokinase component F1, so the anti-thrombotic effect was better than that of natto freeze-dried powder (p<0.01).
[0080]
[0081]
[0082] The invention discloses a method for preparing a natto oligopeptide and its application in thrombolysis and blood pressure reduction. The method uses natto as a raw material, firstly extracts a nattokinase component by ultrafiltration separation, performs peptide sequence detection on the remaining components, counts the proportions of all amino acid residues located at the N-terminus of arginine, designs a composite protease preparation for the site to perform enzymatic hydrolysis on the remaining components, so that the hydrolyzate contains a high L-arginine content, further releases the natto antithrombotic peptide and ACE inhibitory peptide at the same time, and then freeze-dries the nattokinase component and the hydrolyzate to obtain natto oligopeptide powder. The preparation method improves the thrombolytic effect of the final product natto oligopeptide while retaining the nattokinase thrombolytic activity in natto, and combines the vascular regulation effect of L-arginine, so that it has broad prospects in the application of thrombolysis and blood pressure reduction to alleviate thrombotic cardiovascular diseases.
[0083] Example 4 Antithrombotic Effect of Natto Hydrolysate Component F4
[0084] Thirty ICR male mice were randomly divided into a blank control group, a model group, and an antithrombotic group, with 10 mice in each group. The blank group was intraperitoneally injected with a physiological saline solution (0.01 mL / g body weight) every day, the model group was intraperitoneally injected with a 0.20% carrageenan physiological saline solution (0.01 mL / g body weight), and the antithrombotic group was orally fed with natto hydrolysate component F4 (20 mg / g body weight) when the same dose of carrageenan was injected. After 10 days, the length of the black tail of mice in each group was observed and recorded, and blood was collected and tested for four blood coagulation items using a semi-automatic coagulation instrument. The results are shown in Table 3. The model group mice formed a thrombus black tail at the tail, while the length of the tail thrombus of the mice in the natto hydrolysate component F4 intervention group was significantly shorter than that of the model group, and the four coagulation indicators showed significant improvement compared with the model group, indicating that the natto hydrolysate component F4 has a certain antithrombotic activity.
[0085] Table 3. Thrombus length and four coagulation results of mice in each group (n=10)
[0086]
[0087] Compared with the model group, *P<0.01.
[0088] The preparation method of the natto oligopeptide of the present invention uses natto as a raw material, firstly extracts the nattokinase component by ultrafiltration separation, performs peptide sequence detection on the remaining components, counts the proportions of all amino acid residue types located at the N-terminus of arginine, designs a composite protease preparation for the site to perform enzymatic hydrolysis on the remaining components, so that the hydrolyzate contains a high L-arginine content, further releases the natto antithrombotic peptide and ACE inhibitory peptide at the same time, and then freeze-dries the nattokinase component and the hydrolyzate to obtain the natto oligopeptide powder. The preparation method improves the thrombolytic effect of the final product natto oligopeptide while retaining the thrombolytic activity of nattokinase in natto, and combines the vascular regulation effect of L-arginine, and has broad prospects in the application of thrombolysis and blood pressure reduction to alleviate thrombotic cardiovascular diseases.
[0089] Finally, it should be noted that the above examples are only some specific embodiments of the present invention, and all derivatives that can be directly derived or associated with the contents disclosed by a person skilled in the art should be considered as the protection scope of the present invention.
Claims
1. A method for preparing natto antithrombotic functional oligopeptide, characterized in that: include The bioactive peptide database was used to search and determine the characteristics of peptides related to the antithrombotic function of natto. The determined characteristics included a molecular weight of less than 2000 Da, an N-terminal amino acid residue of glycine G, a C-terminal amino acid residue of lysine K or arginine R, and a net charge of ±2; Preparing a natto peptide solution, including a nattokinase component solution and a natto small peptide solution; Sequencing the peptides in the small peptide solution of natto, and according to the sequencing, counting the types and quantities of amino acid residues located before glycine G and the types and quantities of amino acid residues located before arginine R of each peptide in the small peptide solution of natto; According to the statistical quantity, the tyrosine-glycine peptide bond, the phenylalanine-glycine peptide bond, the tyrosine-arginine peptide bond, the lysine carboxyl terminal peptide bond and the arginine carboxyl terminal peptide bond are used as enzyme cleavage sites according to the ranking, and the enzyme cleavage sites are divided by a composite protease, wherein the composite protease is composed of trypsin and chymotrypsin, wherein trypsin: chymotrypsin = 1: (1-3), the enzymatic hydrolysis temperature: 37-45°C, the enzymatic hydrolysis pH: 7.5-8.5, and the enzymatic hydrolysis time: 3-6h; The solution of the cleaved peptides is filtered to collect the solution of peptides with a molecular weight lower than 2000 Da; Separating and purifying the solution of peptides with a molecular weight lower than 2000 Da, collecting the solution of peptides with a net charge of ±2 to obtain a first oligopeptide; Mixing the solution of the peptide with a net charge of ±2 with the solution of the nattokinase component to obtain a second oligopeptide; Wherein, the solution of the nattokinase component is prepared, comprising: Pass the natto powder solution through an ultrafiltration membrane with a molecular weight of 29000Da to obtain a first permeate; Passing the first permeate through an ultrafiltration membrane with a molecular weight of 26000Da to obtain a second permeate and a second intercepted liquid; Wherein, the second intercepted liquid is a solution of the nattokinase component; The preparation of the natto peptide solution comprises adding digestive enzymes to the first permeate and the second intercepted liquid to obtain the natto peptide solution; wherein the digestive enzyme is trypsin; Among them, the steps of sorting according to statistical quantity include: The amino acid residues in front of the different types of glycine G are sorted by quantity; The amino acid residues in the R position before different types of arginine are ranked according to their quantity; According to the ranking of the number of amino acid residues before glycine G of different types, the types of amino acid residues with the largest number or the first few are cut with the peptide bond of glycine G to obtain a peptide with the N-terminal amino acid residue type of glycine G; According to the ranking of the number of amino acids in front of different types of arginine R, the type of amino acid residue with the largest number or the first few largest numbers is cut with the peptide bond of arginine R to obtain a peptide whose N-terminal amino acid residue type is arginine R; The peptide bond at the carboxyl terminal of lysine is cleaved to obtain a peptide whose C-terminal amino acid residue is lysine K; The arginine carboxyl terminal peptide bond of a peptide whose non-N-terminal amino acid residue is arginine R is cleaved to obtain the C-terminal amino acid residue type arginine R, and the arginine R of a peptide whose N-terminal amino acid residue type is arginine R is cleaved to obtain free L-arginine.
2. The method for preparing the antithrombotic functional oligopeptide of natto according to claim 1, characterized in that: in, The step of filtering the cleaved peptide solution comprises filtering the cleaved peptide solution through a nanofiltration membrane with a molecular weight of 2000 Da, wherein the permeate of the nanofiltration membrane is a solution of peptides with a molecular weight lower than 2000 Da; The step of separating and purifying the solution of peptides with a molecular weight lower than 2000Da comprises separating and purifying the solution of peptides with a molecular weight lower than 2000Da by ion exchange chromatography.
3. The method for preparing the antithrombotic functional oligopeptide of natto according to claim 2, characterized in that: The ion exchange chromatography comprises a strong cation exchange column.
4. The method for preparing the antithrombotic functional oligopeptide of natto according to claim 3, characterized in that: The ion exchange chromatography includes a SP Sepharose High Performance strong cation exchange column. After loading, the strong cation exchange column is equilibrated with 20 mmol / L PB, eluted with a 0-40min: 0-1M NaCl concentration gradient, and the eluate is collected for 11-19min to obtain a solution of the peptide with a net charge of ±2.
5. The method for preparing the antithrombotic functional oligopeptide of natto according to claim 1, characterized in that: The natto is prepared from soybeans.
6. The method for preparing the antithrombotic functional oligopeptide of natto according to claim 1, characterized in that: The method also includes freeze-drying the first oligopeptide to obtain natto oligopeptide powder.
7. The method for preparing the antithrombotic functional oligopeptide of natto according to claim 1, characterized in that: The method also includes freeze-drying the second oligopeptide to obtain natto oligopeptide powder.
